Published • loading... • Updated
Kalohexis doses first patients in 710GO Phase I trial for obesity
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Clinical Trials ArenaReposted by 
Verdict Hospital
Verdict HospitalKalohexis doses first patients in 710GO Phase I trial for obesity
Kalohexis has dosed the first patients in its Phase I FIH clinical trial of 710GO, an oral dual MC3R/MC4R agonist to treat general obesity.The post Kalohexis doses first patients in 710GO Phase I trial for obesity appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
